论文部分内容阅读
目的:通过检测单核细胞趋化蛋白-1(MCP-1)和转化生长因子-β1(TGF-β1)在子宫内膜异位症(EMs)中的表达情况,探讨其与EMs分期和痛经评分的关系。方法:选取2012年1月~2013年12月在该院就诊的EMs患者76例为EMs组。按照美国生育协会修正评分(r-AFS)进行分期分为Ⅰ期~Ⅱ期35例,Ⅲ期~Ⅳ期41例;按照痛经评分分为0~1分47例,2~3分29例。另选取同期该院确诊的良性肿瘤患者43例为疾病对照组,该院体检正常妇女15例为正常对照组。观察各组MCP-1和TGF-β1水平的变化,分析EMs不同分期和不同痛经评分与MCP-1和TGF-β1水平的关系。结果:EMs组的MCP-1和TGF-β1表达水平明显高于正常对照组和疾病对照组(P<0.05),而正常对照组和疾病对照组比较,差异无统计学意义(P>0.05)。随着EMs分期和痛经评分的升高,MCP-1和TGF-β1水平明显升高(P<0.05)。结论:MCP-1和TGF-β1可能参与了EMs的发生发展过程,检测其水平有利于了解EMs的分期和痛经的严重程度。
OBJECTIVE: To investigate the expression of MCP-1 and TGF-β1 in endometriosis (EMs) and its relationship with EMs staging and dysmenorrhea Score the relationship. Methods: From January 2012 to December 2013, 76 patients with EMs were selected as EMs group. According to the American Fertility Association Modified Score (r-AFS), 35 cases were stage Ⅰ-Ⅱ and 41 cases were stage Ⅲ-Ⅳ. According to the dysmenorrhea score, there were 47 patients in 0-1, 29 patients in 2-3. In addition, 43 patients with benign tumor diagnosed during the same period were selected as control group and 15 normal women undergoing physical examination in this hospital as normal control group. The changes of MCP-1 and TGF-β1 levels in each group were observed. The relationship between different stages of EMs and different dysmenorrheal scores and the levels of MCP-1 and TGF-β1 were analyzed. Results: The expression of MCP-1 and TGF-β1 in EMs group was significantly higher than that in normal control group and disease control group (P <0.05), but there was no significant difference between normal control group and disease control group (P> 0.05) . The levels of MCP-1 and TGF-β1 were significantly increased as EMs staging and dysmenorrhea score increased (P <0.05). Conclusion: MCP-1 and TGF-β1 may be involved in the development of EMs. To detect the levels of MCP-1 and TGF-β1 is helpful to understand the stages of EMs and the severity of dysmenorrhea.